The research team, led by Martin Vychopen of University Hospital Leipzig together with colleagues including neuroradiologist Karl-Titus Hoffmann and neurosurgeons Erdem Güresir and Johannes Wach, pooled data from six randomized controlled trials encompassing up to 3,044 patients treated for ruptured intracranial aneurysms. Rather than simply averaging outcomes across all patients, as many earlier meta-analyses have done, the investigators stratified their analysis by aneurysm location and by the neurological severity of the hemorrhage at admission, measured on the World Federation of Neurosurgical Societies scale. This anatomically informed approach matters because an aneurysm tucked into the delicate branches of the middle cerebral artery presents a fundamentally different surgical and endovascular challenge than one sitting on the internal carotid artery near the skull base.

The headline finding concerns functional outcome at one year, assessed with the modified Rankin Scale, the standard yardstick of disability after stroke. When the researchers defined a favorable outcome as a score of 0 to 2, meaning the patient is independent in daily life, coiling came out clearly ahead. Across the pooled cohort of 3,044 patients, the odds of achieving independence at one year were 60 percent higher after endovascular coiling than after microsurgical clipping, an odds ratio of 1.60 with a 95 percent confidence interval of 1.36 to 1.88 and a p-value below 0.00001. Critically, heterogeneity across the six trials was essentially zero, indicating that the trials told a remarkably consistent story despite spanning more than two decades of practice.

But here is where the analysis turns provocative. When the team re-ran the numbers using a broader cut-off, defining favorable outcome as a modified Rankin Scale score of 0 to 3, the statistically significant advantage of coiling evaporated entirely. In that analysis of 2,278 patients from three trials, the odds ratio shrank to 1.19 with a p-value of 0.12, well short of significance. The implication is striking: much of the celebrated benefit of coiling may hinge on where exactly the disability scale is divided. This echoes long-standing critiques of the original International Subarachnoid Aneurysm Trial, or ISAT, whose landmark 2005 result established coiling as the preferred treatment in many centers worldwide. Commentators had previously argued that the binary 0-to-2 versus 3-to-6 split was insufficiently sensitive, and the new pooled data, which incorporate the more recent ISAT-2 trial by Darsaut and colleagues, lend quantitative weight to that concern.

The location-specific results are arguably the most clinically actionable part of the study. For aneurysms of the internal carotid artery, coiling delivered a decisive advantage in functional outcome, with an odds ratio of 0.44 favoring coiling, a difference that was highly significant with a p-value below 0.00001 and zero heterogeneity. The authors attribute this to the particular hazards of microsurgical access in this territory: internal carotid artery aneurysms, especially those arising at the ophthalmic segment or the carotid bifurcation, sit in a region where achieving proximal control of the vessel during open surgery can be difficult and may require additional measures to reduce blood flow, raising the morbidity of the surgical approach.

In contrast, no significant difference in one-year functional outcome emerged for aneurysms of the anterior cerebral artery and anterior communicating artery, the middle cerebral artery, or the posterior circulation. For anterior communicating aneurysms, which frequently rupture at small sizes and are associated with complex anatomy such as hypoplasia of the A1 segment, the pooled data support an individualized, anatomy-based decision rather than a default preference for either technique. For posterior circulation aneurysms, which carry elevated in-hospital mortality and a higher incidence of acute hydrocephalus, the analysis was limited by the underrepresentation of basilar and cerebellar aneurysms in prospective randomized trials, a caveat the authors acknowledge openly.

Where clipping decisively reasserts itself is in the durability of aneurysm closure. When the researchers examined complete occlusion confirmed on angiography twelve months after treatment, pooling four trials and 1,889 patients, surgical clipping was clearly superior, with an odds ratio of 0.35, a 95 percent confidence interval of 0.28 to 0.44, and again no heterogeneity. This overall effect, however, was driven almost entirely by one subgroup: middle cerebral artery aneurysms, where the odds of complete occlusion after clipping were more than five times those after coiling, an odds ratio of 5.21 with a p-value of 0.007. For internal carotid, anterior cerebral, and posterior circulation aneurysms, complete occlusion rates did not differ significantly between the two modalities. The anatomical explanation is compelling: middle cerebral artery aneurysms often resemble complex bifurcation lesions rather than simple sacs, frequently involving wide necks and critical branch vessels, and clipping in this location allows the surgeon to preserve distal flow while minimizing the risk of injury to small perforating arteries.

Why does complete occlusion matter so much? Because an incompletely closed aneurysm can reopen, and a reopened aneurysm can bleed again, sometimes catastrophically. The ARETA study found that roughly 20 percent of coiled aneurysms exhibit reopening or neck remnants, with about half of those requiring retreatment, while the CARAT investigation linked the risk of early rebleeding directly to the degree of aneurysm occlusion achieved. The Barrow Ruptured Aneurysm Trial further demonstrated that complete clip occlusion offers superior treatment durability, significantly reducing the need for repeat procedures, and both endovascular and microsurgical retreatment carry higher perioperative complication rates than the original intervention. Achieving complete obliteration in a single procedure therefore remains one of the central therapeutic goals in this disease.

Mortality, meanwhile, refused to pick a side. Across six trials and 2,921 patients, all-cause mortality did not differ between coiling and clipping, with an odds ratio of 0.89 and a p-value of 0.35. The severity-stratified analysis added another layer: among patients with good clinical grades, defined as WFNS grade 3 or better, coiling was associated with significantly better functional outcomes across 2,213 patients, whereas among the 168 patients with the worst grades, WFNS greater than 3, neither technique showed a significant advantage, likely reflecting the dominant influence of the initial brain injury itself on prognosis in severely affected patients.

The authors are careful about the limits of their work. The included trials span more than two decades, during which both endovascular devices and microsurgical techniques have evolved considerably, and modern adjuncts such as the Woven EndoBridge device and stent-assisted coiling are not yet represented in randomized subgroup data. Patients with posterior circulation aneurysms and high-grade hemorrhage remain underrepresented, and complete occlusion was a secondary endpoint in the original trials rather than a pre-specified primary one, introducing the possibility of distribution bias since aneurysm location was not randomly balanced across treatment arms. Risk-of-bias assessment using the Cochrane 2.0 tool rated ISAT and the Barrow Ruptured Aneurysm Trial as low risk across all domains, while other trials raised concerns ranging from unclear randomization to selective reporting. Even so, the core message stands with unusual clarity for a field long divided by tribal loyalties: for a ruptured internal carotid artery aneurysm, the catheter likely holds the edge in preserving independence at one year; for a ruptured middle cerebral artery aneurysm, the clip remains the gold standard for sealing the lesion completely and durably; and for everything in between, the decision deserves to be made aneurysm by aneurysm, patient by patient, balancing the promise of functional recovery against the imperative of permanent closure.

Subject of Research: Comparative effectiveness of endovascular coiling versus microsurgical clipping for ruptured intracranial aneurysms

Article Title: Efficacy and safety of endovascular coiling compared to microsurgical clipping in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of randomized trials

Article References: Vychopen, M., Hoffmann, K.-T., Güresir, E., & Wach, J. (2026). Efficacy and safety of endovascular coiling compared to microsurgical clipping in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of randomized trials. Journal of Neurology, 273(10), Article 650. https://doi.org/10.1007/s00415-026-14150-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14150-z

Keywords: aneurysmal subarachnoid hemorrhage, endovascular coiling, microsurgical clipping, intracranial aneurysm, meta-analysis, randomized controlled trials, modified Rankin Scale, middle cerebral artery, internal carotid artery, complete occlusion, ISAT, neurosurgery

The review, led by Táya Figueiredo de Oliveira Fiore and colleagues, prospectively registered in PROSPERO and conducted under the PRISMA 2020 and SWiM reporting frameworks, synthesized 20 reports encompassing 11,096 participant records with confirmed aSAH. The studies, published between 2015 and 2026, spanned Asia, Europe, South America, North America and Oceania, and compared clinical outcomes across different onset-to-treatment windows ranging from less than six hours to fifteen days or more. Eighteen of the studies were retrospective cohorts and two were post hoc analyses of randomized trial data — but crucially, in none of them was treatment timing actually randomized, making every comparison observational by nature.

The team’s central question was deceptively simple: does the interval between aneurysm rupture and definitive repair — whether by microsurgical clipping or endovascular coiling — independently determine mortality, functional recovery, and complications such as rebleeding, vasospasm, delayed cerebral ischemia, hydrocephalus, and length of hospital stay? To answer it, the reviewers weighted propensity-adjusted and comprehensively adjusted multivariable analyses far more heavily than crude or descriptive comparisons, and graded the certainty of evidence using the GRADE framework. For the timing-mortality association, certainty was downgraded to very low — the lowest possible category — because of serious risk of bias, inconsistency, and imprecision.

One finding stood out with relative clarity: earlier aneurysm securement genuinely reduces pretreatment rebleeding, the catastrophic rerupture that can occur while the aneurysm remains unsecured. Studies that included untreated or markedly delayed patients showed dramatic gradients. In one cohort, rebleeding occurred in seven percent of patients treated within 24 hours, ten percent treated at 24 to 72 hours, and 38 percent treated after 72 hours — with 16 percent of untreated patients also bleeding. Another study reported rebleeding in zero percent of patients clipped within six hours versus 49.1 percent of those never repaired. These comparisons align with classic data showing that ultra-early treatment within six hours cuts rebleeding risk dramatically, and they underpin the 2023 American Heart Association/American Stroke Association Class 1 recommendation to treat as early as feasible, ideally within 24 hours of onset.

Beyond rebleeding, however, the evidence became murky. Across 19 studies reporting functional outcome, eight favored earlier treatment, four favored later treatment, four found no independent association after adjustment, and three showed non-significant trends. The most methodologically robust analyses — those adjusting for baseline clinical severity measured on the WFNS and Hunt-Hess scales — were predominantly null. Significant adjusted associations favoring early repair tended to arise in studies plagued by treated-survivor selection, incomplete confounder control, or composite exposure definitions. Mortality data were similarly discordant: two analyses favored earlier treatment, three favored later treatment, and four found no difference at all.

The most provocative results came from the only two studies that modeled onset-to-treatment time as a continuous variable rather than forcing patients into arbitrary cutoffs like under or over 24 hours. Using flexible cubic spline models, one large multicenter analysis of 3,560 patients identified a statistically significant U-shaped relationship between treatment time and mortality, with the estimated risk lowest at approximately 32.6 hours. The other study found a similar but non-significant pattern with a nadir near 12.2 hours. These nonlinear curves may help reconcile the seemingly contradictory findings of decades of dichotomous timing studies — but the reviewers are emphatic that they are hypothesis-generating only, not a validated therapeutic window.

Why would a mid-range interval appear optimal? The answer lies in two insidious statistical traps. The first is confounding by indication: the sickest patients, those with the worst WFNS and Hunt-Hess grades, are treated most urgently, making early treatment appear spuriously harmful in unadjusted comparisons. The second is survivor bias: a patient can only appear in a delayed-treatment group if they survive long enough to reach it, making later treatment appear spuriously beneficial. Neither bias can be fully corrected in retrospective analyses, no matter how sophisticated the propensity matching. Strikingly, in one trial analysis, the apparent excess risk of ultra-early treatment attenuated almost entirely once patients who rebled early were reclassified or excluded.

The review also examined whether the choice of repair technique modifies the timing effect. Of three studies that formally tested a modality-timing interaction, only one — the same large continuous-time analysis — found a significant interaction for mortality, with the U-shaped curve more pronounced in the microsurgical group and more gradual in the endovascular group. The other two found nothing, and stratified analyses showed no consistent modality-specific pattern. Direct clipping-versus-coiling comparisons across the included studies were heterogeneous and outcome-specific, with no consistent independent advantage for either technique after adjustment, echoing the broader randomized evidence that favors coiling in suitable patients but shows convergence in risk-adjusted contemporary cohorts.

For the secondary outcomes, the timing signal essentially vanished. Neither continuous-time analysis found any association between treatment time and delayed cerebral ischemia or postoperative cerebral ischemia. Hydrocephalus showed no reproducible link, with one unadjusted finding of more shunt-dependent hydrocephalus after early treatment likely reflecting the simple fact that sicker patients get treated sooner. Length of stay was underexplored and discordant. Isolated subgroup findings — such as higher infarction risk with treatment beyond 24 hours in moderate-grade patients, or increased procedural risk when operating during the vasospasm phase — were not reproduced across overall populations.

The reviewers conclude that current guidelines remain firmly supported: aneurysms should be secured as early as feasible, and nothing in the evidence justifies intentional delay or a specific alternative timing target. But they also issue a clear call to arms for the field. Future research must model treatment time as a continuous exposure using restricted cubic splines, rigorously adjust for clinical severity and age, stratify by modality with formal interaction testing, and — critically — include patients who die before treatment, whose absence from nearly every existing cohort distorts the entire evidence base. The review also cautions that its findings, generated predominantly in high-volume centers in Asia and Europe, may not translate to settings where patients arrive days after onset; cohorts in middle-income countries have reported median ictus-to-treatment intervals of four to nine days. Until prospective multicenter registries with standardized definitions deliver cleaner data, the race against the clock continues — guided by the one outcome where speed undeniably matters: stopping the aneurysm before it bleeds again.

Subject of Research: The association between onset-to-treatment time and clinical outcomes after aneurysmal subarachnoid hemorrhage

Article Title: Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review

Article References: Fiore, T. F. D. O., Vieira, Â. M. A., Magalhães, F. D. F., de Souza, C. G., Alves Filho, C. A. F., & Barboza, T. (2026). Timing of aneurysm repair and clinical outcomes after aneurysmal subarachnoid hemorrhage: a systematic review. Journal of Neurology, 273(10), Article 582. https://doi.org/10.1007/s00415-026-14063-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14063-x

Keywords: aneurysmal subarachnoid hemorrhage, aneurysm repair timing, rebleeding, microsurgical clipping, endovascular coiling, mortality, functional outcome, confounding by indication, survivor bias, delayed cerebral ischemia, systematic review, neurocritical care